Oksazolidinonların ve Daptomisinin Etki Spektrumu ve Kullanım Alanları

Usluer G, Ünal S. Linezolid. Flora Enfeksiyon Hastalıkları ve Klinik

Mikrobiyoloji Dergisi. 2005;10 (ek 4); 1-15

Moellering R. C. Linezolid: the first oxazolidinone antimicrobial. Annals of internal medicine, 2003; 138(2), 135–142. https://doi.org/10.7326/0003-4819-138-2-200301210-00015

Luque S, Grau S, Alvarez-Lerma F, et al. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. International Journal of Antimicrobial Agents. 2014;44(5):409-415. doi:10.1016/j.ijantimicag.2014.07.001

MacGowan A. P. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. The Journal of antimicrobial chemotherapy, 2013; 51 Suppl 2, ii17–ii25. https://doi.org/10.1093/jac/dkg248

Willke A, Doganay M, Söyletir G, Nobel Kitabevi, İstanbul, 2008; cilt 1: 337-41.

Crass, R. L., Cojutti, P. G., Pai, M. P., et al, Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Antimicrobial agents and chemotherapy, 2019; 63(8), e00605-19. https://doi.org/10.1128/AAC.00605-19

Douros, A., Grabowski, K., & Stahlmann, R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert opinion on drug metabolism & toxicology, 2015; 11(12), 1849–1859. https://doi.org/10.1517/17425255.2015.1098617

Stalker, D. J., & Jungbluth, G. L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clinical pharmacokinetics, 2003; 42(13), 1129–1140. https://doi.org/10.2165/00003088-200342130-00004

Wilcox M. H. Update on linezolid: the first oxazolidinone antibiotic. Expert opinion on pharmacotherapy, 6(13), 2005; 2315–2326. https://doi.org/10.1517/14656566.6.13.2315

Diekema, D. J., & Jones, R. N. Oxazolidinone antibiotics. Lancet 2005; 358(9297), 1975–1982. https://doi.org/10.1016/S0140-6736(01)06964-1

Ager, S., & Gould, K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infection and drug resistance, 2012; 5, 87–102. https://doi.org/10.2147/IDR.S25890

Larruskain J, Idıgoras P, Marimon JM et al. “Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents.” Antimicrobial agents and chemotherapy 2011 ; vol. 55,6 2995-8. doi:10.1128/AAC.01279-10

Lifan, Z., Sainan, B., Feng, S., et al. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2019; 23(12), 1293–1307. https://doi.org/10.5588/ijtld.18.0822

Stevens, D. L., Dotter, B., & Madaras-Kelly, K. A review of linezolid: the first oxazolidinone antibiotic. Expert review of anti-infective therapy, 2004; 2(1), 51–59. https://doi.org/10.1586/14787210.2.1.51

Zyvox® (linezolid) [package insert]. New York: Pharmacia and Upjohn Company; 2017.

Hashemian, S. M. R., Farhadi, T., & Ganjparvar, M. Linezolid: a review of its properties, function, and use in critical care. Drug design, development and therapy, 2018; 12, 1759–1767. https://doi.org/10.2147/DDDT.S164515

Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296

Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. The New England journal of medicine, 2012; 367(16), 1508–1518. https://doi.org/10.1056/NEJMoa1201964

Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrobial agents and chemotherapy, 2002; 46(8), 2723–2726. https://doi.org/10.1128/AAC.46.8.2723-2726.2002

Narita, M., Tsuji, B. T., & Yu, V. L. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy, 2007; 27(8), 1189–1197. https://doi.org/10.1592/phco.27.8.1189

Ortiz-Covarrubias A, Fang E, Prokocimer PG, et al. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2016; 20(2), 184–192. https://doi.org/10.1016/j.bjid.2015.12.007

Roger, C., Roberts, J. A., & Muller, L. Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. Clinical pharmacokinetics, 2018; 57(5), 559–575. https://doi.org/10.1007/s40262-017-0601-x

Flanagan, S., Bartizal, K., Minassian, S. L., et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrobial agents and chemotherapy, 2013; 57(7), 3060–3066. https://doi.org/10.1128/AAC.00431-13

Kosmidis, C., & Levine, D. P. Daptomycin: pharmacology and clinical use. Expert opinion on pharmacotherapy, 11(4), 2010; 615–625. https://doi.org/10.1517/14656561003598893

Hair, P. I., & Keam, S. J. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs, 2007; 67(10), 1483–1512. https://doi.org/10.2165/00003495-200767100-00008

Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrobial agents and chemotherapy, 2003; 47(4), 1318–1323. https://doi.org/10.1128/AAC.47.4.1318-1323.2003

Sauermann, R., Rothenburger, M., Graninger, W., & Joukhadar, C. Daptomycin: a review 4 years after first approval. Pharmacology, 2008; 81(2), 79–91. https://doi.org/10.1159/000109868

Silverman, J. A., Mortin, L. I., Vanpraagh, A. et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. The Journal of infectious diseases, 2005; 191(12), 2149–2152. https://doi.org/10.1086/430352

Vena A, Falcone M, Comandini E, et al. Daptomycin plus trimethoprim/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant Staphylococcus epidermidis. Diagnostic microbiology and infectious disease, 2013; 76(1), 99–102. https://doi.org/10.1016/j.diagmicrobio.2013.01.021

Chuma M, Nakamoto A, Bando T, et al. Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022; 75(8), 1416–1422. https://doi.org/10.1093/cid/ciac128

Humphries, R. M., Pollett, S., & Sakoulas, G. A current perspective on daptomycin for the clinical microbiologist. Clinical microbiology reviews, 2013; 26(4), 759–780. https://doi.org/10.1128/CMR.00030-13

Moore, C. L., Osaki-Kiyan, P., Haque, N. et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012; 54(1), 51–58. https://doi.org/10.1093/cid/cir764

Sakoulas, G., Golan, Y., Lamp, K. et al. Daptomycin in the treatment of bacteremia. The American journal of medicine, 2007; 120(10 Suppl 1), S21–S27. https://doi.org/10.1016/j.amjmed.2007.07.012

Chaftari AM, Hachem R, Mulanovich V, et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. International journal of antimicrobial agents, 2010; 36(2), 182–186. https://doi.org/10.1016/j.ijantimicag.2010.03.015

Cantoni, L., Glauser, M. P., & Bille, J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrobial agents and chemotherapy, 1990; 34(12), 2348–2353. https://doi.org/10.1128/AAC.34.12.2348

Skiest D. J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. Journal of clinical microbiology, 2006; 44(2), 655–656. https://doi.org/10.1128/JCM.44.2.655-656.2006

Knoll, B. M., Spieler, P. J., Kubiak, D. W. et al. Neutropenia associated with prolonged daptomycin use. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013; 56(9), 1353–1354. https://doi.org/10.1093/cid/cit023

Daptomycin (Cubicin) Product Information. Merck and Co, Inc; Whitehouse, NJ 8/2020

Hirai J, Hagihara M, Haranaga S, et al. Eosinophilic pneumonia caused by daptomycin: Six cases from two institutions and a review of the literature. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2017; 23(4), 245–249. https://doi.org/10.1016/j.jiac.2016.09.001